Vinorelbine
Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 73/ 100
Competitive context
28 Active assets in the Diffuse Large B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Mwanasha Merrill, MD | Phase 4 | BB |
Tucidinostat Rong Tao | Phase 3 | BB |
Tislelizumab The First Affiliated Hospital with Nanjing Medical University | Phase 3 | BB |
Everolimus University of California, Davis | Phase 3 | BB |
Zilovertamab Vedotin Merck Sharp & Dohme LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →